## CLAIMS

1. Use of a combination of a tumor necrosis factor receptor superfamily (TNFRSF) agonist or a functional fragment thereof and an interferon (IFN) agent or a functional fragment thereof, for preparing a medicament for use for treating a HBV infection~~.~~,

~~2. The use according to claim 1,~~ wherein the TNFRSF agonist or a functional fragment thereof is ~~selected from the group consisting of a lymphotoxin alpha 3 receptor agonist, a lymphotoxin beta receptor agonist, a herpesvirus entry mediator agonist, a tumor necrosis factor-like receptor weak inducer of apoptosis agonist, a cluster of differentiation factor 40 agonist, a CD27 agonist, a CD30 agonist, a 4-1BB agonist, a receptor activator of nuclear factor κB agonist, a Troy agonist, and a OX40 receptor agonist, or functional fragments thereof.~~

~~3. The use according to claim 1 or 2, wherein the TNFRSF agonist or~~ TWEAK, or a functional fragment thereof ~~is selected from the group consisting of CD40L, LTα3, LIGHT and TWEAK, or functional fragments thereof.~~.

~~4. The use according to any one of claims 1 to 3,~~ 2.Use of a bifunctional immunostimulatory fusion protein for preparing a medicament for use for treating a HBV infection, the bifunctional immunostimulatory fusion protein comprising a tumor necrosis factor receptor superfamily (TNFRSF) agonist or a functional fragment thereof, an interferon (IFN) agent or a functional fragment thereof, and a linker,

wherein the TNFRSF agonist or a functional fragment thereof is ~~selected from the group consisting of CD40L, LIGHT and~~ TWEAK, or a functional ~~fragments~~fragment thereof.

3. The use according to claim ~~5, wherein the CD40L is hexameric CD40L or trimeric CD40L.~~

~~7. The use according to any one of claims 1 to 6, wherein the TNFRSF agonist or a functional fragment thereof is a polypeptide or a functional fragment thereof, an antibody or a functional fragment thereof, or an antigen-binding fragment thereof.~~

~~8. The use according to any one of claims 1 to 7, wherein the TNFRSF agonist or a functional fragment thereof is provided as a fusion protein comprising said TNFRSF agonist or a functional fragment thereof.~~

~~9. The use according to any one of claims 1 to 8~~1 or 2, wherein the IFN agent or a functional fragment thereof is selected from the group consisting of a Type I IFN agent, a Type II IFN agent and a Type III IFN agent, or functional fragments thereof.

~~10~~4. The use according to any one of claims 1 to ~~9~~3, wherein the IFN agent or a functional fragment thereof is IFNα, IFNβ, IFNγ or IFNλ, or functional fragments thereof.

~~11~~5. The use according to any one of claims 1 to ~~10~~4, wherein the IFN agent or a functional fragment thereof is IFNβ or- IFNγ, or functional fragments thereof.

~~12~~6. The use according to any one of claims 1 to ~~11~~5, wherein the IFN agent or a functional fragment thereof is IFNβ, or a functional fragment thereof.

~~13~~7. The use according to any one of claims 1 to ~~10~~4, wherein the IFN agent or a functional fragment thereof is IFNα, or a functional fragment thereof.

~~14.~~ 8. The use according to any one of claims 1 ~~to 13, wherein the IFN agent or a functional fragment thereof is provided as a fusion protein comprising said IFN agent or a functional fragment thereof.~~

~~15. The use according to any one of claims 1 to 14, wherein the TNFRSF agonist or a functional fragment thereof and the IFN agent or a functional fragment thereof are provided as a bifunctional immunostimulatory fusion protein comprising the said TNFRSF agonist or a functional fragment thereof, the said IFN agent or a functional fragment thereof and a linker.~~

~~16. The use according to any one of claims 1 to 15~~or 3 to 7, wherein the TNFRSF agonist or a functional fragment thereof and the IFN agent or a functional fragment thereof are comprised in a single pharmaceutical composition.

~~17~~9. The use according to any one of claims 1 or 3 to ~~14~~7, wherein the TNFRSF agonist or a functional fragment thereof and the IFN agent or a functional fragment thereof are comprised in distinct pharmaceutical compositions.

~~18~~10. The use according to any one of claims 2 to 7, wherein the linker is a peptide linker incorporating a multimerization domain.

11. The use according to claim 10, wherein the multimerization domain is selected among a tenascin trimerization motif, a collectin trimerization domain, streptavidin, an IgE heavy-chain domain 2 (EHD2), an IgM heavy-chain domain 2 (MHD2), an IgG heavy-chain domain 3 (GHD3), an IgA heavy-chain domain 3 (AHD2), an IgD heavy-chain domain 3 (DHD3), an IgE heavy-chain domain 4 (EHD4), an IgM heavy-chain domain 4 (MHD4), an Fc domain, an uteroglobin dimerization domain and a leucine zipper (LZ) domain.

12. A pharmaceutical composition comprising:

a TNFRSF agonist or a functional fragment thereof; and

~~a Type II~~ an interferon (IFN) agent~~,~~ or a functional fragment ~~of a Type II IFN agent, a Type III IFN agent,~~thereof

wherein the TNFRSF agonist or a functional fragment ~~of~~thereof is TWEAK, or a functional fragment thereof.

13. A pharmaceutical composition comprising a bifunctional immunostimulatory fusion protein comprising a tumor necrosis factor receptor superfamily (TNFRSF) agonist or a ~~Type III IFN agent.~~functional fragment thereof, an interferon (IFN) agent or a functional fragment thereof, and a linker,

~~19.~~ wherein the TNFRSF agonist or a functional fragment thereof is TWEAK, or a functional fragment thereof.

14. A combination of a tumor necrosis factor receptor superfamily (TNFRSF) agonist or a functional fragment thereof and an interferon (IFN) agent or a functional fragment thereof, for use for treating a HBV infection.,

wherein the TNFRSF agonist or a functional fragment thereof is TWEAK, or a functional fragment thereof.

15. A bifunctional immunostimulatory fusion protein comprising a tumor necrosis factor receptor superfamily (TNFRSF) agonist or a functional fragment thereof, an interferon (IFN) agent or a functional fragment thereof, and a linker, for use for treating a HBV infection,

wherein the TNFRSF agonist or a functional fragment thereof is TWEAK, or a functional fragment thereof.

16. The pharmaceutical composition according to claims 12 or 13, the combination according to claim 14 or the bifunctional immunostimulatory fusion protein according to claim 15, wherein the IFN agent is according to any one of claims 3 to 7.